Furthermore, although pediatric AML represent a genetically distinct disease entity [15] , when the AS-15 score was applied to pediatric AML, a highly significant prognostic power was observed in both infants (<3 years) and adolescents (3–24 years).
← all excerpts
Prognostic alternative mRNA splicing signatures and associated splicing factors in acute myeloid leukemia.
1
—
—